Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) in a report released on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Bicara Therapeutics’ FY2024 earnings at ($1.61) EPS.
BCAX has been the subject of several other reports. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday. They issued a buy rating and a $47.00 price target for the company. TD Cowen began coverage on Bicara Therapeutics in a report on Tuesday. They issued a buy rating on the stock. Finally, Morgan Stanley started coverage on Bicara Therapeutics in a report on Tuesday. They set an overweight rating and a $35.00 target price for the company.
View Our Latest Research Report on Bicara Therapeutics
Bicara Therapeutics Price Performance
Insider Buying and Selling at Bicara Therapeutics
In other news, major shareholder James E. Flynn acquired 70,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares of the company’s stock, valued at $16,156,566. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Bicara Therapeutics news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares in the company, valued at $77,461,524. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder James E. Flynn acquired 70,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here.
Bicara Therapeutics Company Profile
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
- Five stocks we like better than Bicara Therapeutics
- Short Selling: How to Short a Stock
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What Are Dividend Achievers? An Introduction
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Election Stocks: How Elections Affect the Stock Market
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.